Drug Profile
Apricoxib
Alternative Names: Capoxigem; CS-706; Kymena; R-109339; TG 01; TP1001 programme; TP2001 programmeLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer Tragara Pharmaceuticals
- Class Anti-inflammatories; Antineoplastics; Pyrroles; Small molecules; Sulfonamides
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Inflammation; Inflammatory pain; Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 03 Jan 2019 Tragara Pharmaceuticals is now called Adastra Pharmaceuticals
- 09 Jul 2015 Tragara Pharmaceuticals completes a phase II trial in Non-small cell lung cancer (Combination therapy, late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (NCT00771953)
- 07 Jun 2011 Final efficacy data from the phase II APRiCOT-L trial in recurrent late-stage or metastatic Non-small cell lung cancer (second-line therapy, in combination with erlotinib) presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO-2011)